Moderna, Inc.’s Stock Price Plummets to $35.15, Witnessing a Drastic 16.80% Drop

Moderna, Inc. (MRNA)

35.15 USD -7.10 (-16.80%) Volume: 33.38M

Moderna, Inc.’s stock price currently stands at 35.15 USD, experiencing a substantial drop of -16.80% this trading session with a high trading volume of 33.38M. The biotechnology company’s stock has also seen a year-to-date decrease of -17.80%, reflecting a challenging market environment for MRNA investors.

Latest developments on Moderna, Inc.

Moderna has been facing a tumultuous period as the company shocked investors by predicting a larger-than-expected drop in sales. This announcement came amidst other Massachusetts biotech firms making waves at the JPMorgan Healthcare Conference. The biotech giant revealed that it is getting closer to developing a norovirus vaccine, but this positive news was overshadowed by a $1 billion cut to its 2025 sales forecast due to weak vaccine demand. As a result, Moderna’s stock price plummeted by 20%, marking one of its worst days ever. The company is now looking to implement $1.5 billion in cost cuts to offset the decline in revenue and navigate through this challenging period.

Moderna, Inc. on Smartkarma

Analysts at Baptista Research have published two bullish reports on Moderna Inc. on Smartkarma. The first report titled “Moderna Inc.: Expanding Global Presence For Unmatched Impact! – Major Drivers” highlights the company’s financial results for the third quarter of 2024, showcasing $1.9 billion in revenue, $13 million in net income, and $9.2 billion in cash and investments. This strong financial position positions Moderna well for future initiatives. The second report, “Moderna Inc.: These Are The 4 Biggest Challenges That Bears Are Counting On! – Major Drivers,” focuses on the company’s Quarterly Earnings performance, emphasizing advancements in Moderna’s respiratory vaccine portfolio, including mRNA-1273 for COVID-19 and mRESVIA for RSV.

A look at Moderna, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Moderna, Inc. is showing promising signs for its long-term outlook based on the Smartkarma Smart Scores. With strong scores in value and resilience, the company is positioned well for future growth and stability. While its growth and momentum scores are not as high, Moderna’s focus on mRNA therapeutics and vaccines could drive innovation and potential success in the biotechnology sector.

As a biotechnology company, Moderna, Inc. is dedicated to the development of messenger RNA medicines for various diseases. While its dividend score is low, the company’s emphasis on infectious, immuno-oncology, and cardiovascular diseases showcases its commitment to addressing critical health issues. With a solid value score and decent scores in resilience and momentum, Moderna has the potential to make significant advancements in the biotech field in the coming years.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma